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Summary
Aging is associated with a progressive loss of the CD28 costim-
ulatory molecule in CD4+ lymphocytes (CD28null T cells), which is
accompanied by the acquisition of new biological and functional
properties that give rise to an impaired immune response. The
regulatory mechanisms that govern the appearance and function
of this cell subset during aging and in several associated
inflammatory disorders remain controversial. Here, we present
the whole-genome DNA methylation and gene expression pro-
files of CD28null T cells and its CD28+ counterpart. A comparative
analysis revealed that 296 genes are differentially methylated
between the two cell subsets. A total of 160 genes associated
with cytotoxicity (e.g. GRZB, TYROBP, and RUNX3) and cytokine/
chemokine signaling (e.g. CX3CR1, CD27, and IL-1R) are demethy-
lated in CD28null T cells, while 136 de novo-methylated genes
matched defects in the TCR signaling pathway (e.g. ITK, TXK,
CD3G, and LCK). TCR-landscape analysis confirmed that CD28null T
cells have an oligo/monoclonal expansion over the polyclonal
background of CD28+ T cells, but feature a Vb family repertoire
specific to each individual. We reported that CD28null T cells show
a preactivation state characterized by a higher level of expression
of inflammasome-related genes that leads to the release of IL-1b
when activated. Overall, our results demonstrate that CD28null T
cells have a unique DNA methylation landscape, which is
associated with differences in gene expression, contributing to
the functionality of these cells. Understanding these epigenetic
regulatory mechanisms could suggest novel therapeutic strate-
gies to prevent the accumulation and activation of these cells
during aging.
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Introduction
During differentiation and homeostatic proliferation of CD4+ T lympho-
cytes, some cells lose expression of the CD28 costimulatory molecule,
which is fundamental to the activation, proliferation and survival of
CD4+ T cells (Vallejo et al., 2002). CD4+ CD28null cells (now known as
CD28null T cells) acquire new phenotypic and functional characteristics
compared with those of conventional CD4+CD28+ (named as CD28+) T
cells (Maly & Schirmer, 2015). An increase in the percentage of CD4+
CD28null T cells with age has been reported not only in healthy donors
(Weng et al., 2009), but also in patients with infections (CMV, HCV,
HIV), inflammatory disorders, autoimmune diseases (rheumatoid arthri-
tis, ankylosing spondylitis, multiple sclerosis), and cardiovascular dis-
eases, or in solid organ transplantation (Scarsi et al., 2011; Broux et al.,
2012; Teo et al., 2013; Shabir et al., 2016). The appearance of this
subset during aging can compromise the CD4+ T-cell compartment,
leading to a reduced immune response to pathogens and vaccines in the
elderly. By contrast, this CD28null subset is only detectable in a low
percentage of young and middle-aged individuals, although it is
sometimes highly enriched in the CD4+ T-cell compartment.
The nature of the stimuli that trigger expansion of these CD28null T
cells is not fully understood. Some studies suggest that they are
generated in response to repeated specific auto-antigen stimulation,
while others show that they respond to ubiquitous antigens such as
heat-shock proteins (Hsp 60) and viral antigens (proteins from CMV),
thereby acquiring an innate T-cell-like phenotype (Zal et al., 2004; van
Bergen et al., 2009). Some therapeutic approaches have been proposed
with the purpose of reducing the percentage of CD28null T cells, such as
activation in the presence of IL-12 or treatments with statins, abatacept,
or ATG (Warrington et al., 2003; Link et al., 2011; Scarsi et al., 2011;
Duftner et al., 2012). However, the basic mechanisms leading to the
generation of CD28null T cells remain unknown. Knowledge of them
might suggest new therapeutic options to prevent its accumulation and
function.
Aging has been associated with gradual DNA methylation changes
over the lifespan, marked by global hypomethylation and specific
hypermethylation in promoter-associated CpG islands (Martin, 2005;
Heyn et al., 2012). Some studies have linked these changes to
alterations in the expression levels of DNMT1 and DNMT3B regardless
of nutritional habits, lifestyle, or clinical parameters (Ciccarone et al.,
2016). In this way, age-associated ‘epigenetic drift’ can potentially
restrict the plasticity of T cells while supporting new phenotypes, such as
exhausted or senescent T cells (Fraga et al., 2005; Issa, 2014). Moreover,
it has recently been shown that changes in DNA methylation levels in
certain CpG sites are closely associated with the age of individuals
(Florath et al., 2014). This ‘epigenetic clock’ demonstrates that using a
small number of these sites can accurately predict the chronological age
of an individual. DNA methylation is a key process in hematopoietic
differentiation and the maintenance of subset-specific T lymphocyte
gene expression (Calvanese et al., 2012; Rodriguez et al., 2015). The
regulatory regions of some specific genes and transcription factors are
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demethylated, and therefore, the genes are overexpressed in certain T
subsets (e.g. IFNG in Th1 cells), while others are repressed by de novo
methylation at regulatory regions (e.g. IFNG and FOXP3 in Th2 cells;
Suarez-Alvarez et al., 2013). However, these methylation patterns can
be altered in response to intrinsic or external stimuli, causing changes in
gene expression (Agrawal et al., 2010; Suarez-Alvarez et al., 2012). In
CD28null T lymphocytes, low levels of Dnmt1 and Dnmt3a lead to a loss
of methylation and overexpression of CD70, perforin, and KIR2DL4 (Liu
et al., 2009).
Here, we examined the whole-genome DNA methylation and
expression profiles of CD28null and CD28+ T-cell subsets. We identified
296 differentially methylated genes related to defects in TCR signaling,
cell death pathways, and cytotoxicity ability. Alterations in the expression
of genes related to the inflammasome pathway suggest the presence of
a preactivated inflammatory phenotype in CD28null T cells. Our results
indicate that specific changes in DNA methylation dynamics in conven-
tional CD4+ T cells contribute to the acquisition and maintenance of the
CD28null phenotype that may predispose individuals to age-associated
decline in their immune response.
Results
Overall gain of gene expression in CD28null T cells is
associated with changes in immune response and
programmed cell death
We analyzed the differential gene expression between CD28null T cells
and their CD28+ counterparts isolated from healthy donors at different
ages to avoid changes due to pathologies. To minimize the differences
among individuals, samples were grouped into two pools of 12 donors
each (range: 45–75 years; average: 62.1  9.9 years). We identified
1978 differentially expressed genes (DEGs; adjusted P < 0.01 and
FC ≥ 1.5 or ≤ 1.5), of which 1205 (60.9%) were upregulated and
773 (39.1%) were downregulated in CD28null relative to their CD28+
counterparts (Table S1, Supporting information). An overall gain of gene
expression was observed in the CD28null T cells regardless of the fold-
change criteria used (Fig. S1A, Supporting information). To study the
biological functions involving these genes, we performed GO analysis
using more severe criteria (adjusted P < 0.01 and FC ≥ 3 or ≤ 3; 545
upregulated and 125 downregulated genes). We observed that GO
terms related to immune response (GO: 0006955), regulation of
programmed cell death (GO: 0043067), defense response (GO:
0006952), and cell activation (GO: 0001775) were markedly enriched
in CD28null T cells (Fig. S1B and Table S2, Supporting information).
Genes related to immune and defense responses were upregulated in
CD28null cells, while loss of expression was associated with a wider range
of functions, such as response to stress, the macromolecule catabolic
process, chromatin modifications, and cell death (Fig. S2 and Table S2,
Supporting information). KEGG analysis showed that DEGs are enriched
in pathways related to autoimmune diseases, infections or allograft
rejection, in which the functionality of these CD28null T cells had been
previously demonstrated (Fig. S1C and Table S2, Supporting informa-
tion).
We then analyzed in detail the two most significantly altered
functional categories—immune response and regulation of programmed
cell death—by considering all the DEGs within each category (P < 0.01
and FC ≥ 1.5 or ≤ 1.5). Our results showed that most of the DEGs
related to the immune system (94 of 112 genes, 84%) were overex-
pressed in CD28null T cells, suggesting a gain of immune functions in
these cells (Fig. 1). Some of these genes correspond to receptors that are
strongly expressed in NK cells (LILRB3, LILRB2), chemokines (CCR6,
CCL20), cytokines (IL-10, IL-18, IL-6R, IL-1R2), and adhesion molecules
(CD14, CD1C, CD86, TNFSF8, TNFSF13B, TNFSF14), which regulate the
migration and recruitment of other cell types. The genes involved in the
interferon (IFN) pathway, such as IRF8 transcription factor (TF), were also
more strongly expressed. This gene regulates expression of LST1 protein,
which inhibits lymphocyte proliferation. Other autoimmunity-related TFs,
such as ETS-1 and AIRE, were also upregulated. Conversely, the loss of
CD40LG gene expression in CD28null T cells could involve defects in the
interaction and activation of B cells.
One of the main characteristics of CD28null cells is their resistance to
programmed cell death (Kovalcsik et al., 2015). We observed a clear
deregulation of the expression levels of the Bcl-2 (B-cell lymphoma-2)
family members. CD28null T cells expressed high levels of the antiapop-
totic genes BCL2, BCL2L1 (encoding Bcl-x), and MCL-1, while the
pro-apoptotic genes BAX and BCL2L11 (BIM) were significantly down-
regulated (Fig. 1). These data correlates with the low levels of Annexin V
staining observed in CD28null T cells before and after staurosporine-
Fig. 1 Volcano plots of genes associated with the most representative categories,
immune response and regulation of programmed cell death, and differentially
expressed in CD28null T cells. Gray dots indicate all DEGs between CD28+ and
CD28null T cells. Genes associated with the immune response (GO:0006955) and
programmed cell death (GO: 0043067) categories are highlighted in blue and red,
respectively. For this analysis, the criteria of adjusted P < 0.01 and ≥ 1.5-fold
change in size were used. Numbers in the corners show the number of genes
upregulated and downregulated in CD28null T cells in each functional category.
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induced apoptosis and in comparison with their CD28+ counterparts
(Fig. S3, Supporting information). Moreover, expression of negative
apoptosis regulators such as CFLAR (also known as FLIP or CASPER), BIRC2
(cIAP-1) and BIRC3 (cIAP-2) was stronger in these cells, in contrast to the
downregulation of the positive regulator DIABLO, which is involved in
caspase activation. Other genes related to necroptosis, such as RIPK1 and
MLKL, were also underexpressed in CD28null cells.
CD28null T cells overexpress genes involved in the
inflammasome pathway
We found that all genes comprising the NLRP3-inflammasome complex
were overexpressed in CD28null cells (Fig. 2A). These included the NOD-
like receptor (NLR) pyrin domain containing 3 (NLRP3), the ASC adaptor
protein encoded by the PYCARD gene, the caspase recruitment domain
family member 8 (CARD8), and the inactive pro-form caspase-1 (CASP1).
Together, they form a multimolecular protein complex, which is essential
for the cleavage of caspase-1 into its active form. The pro-forms of the
IL-1B and IL-18 genes were also significantly more strongly expressed
in CD28null T cells. To corroborate these findings, we analyzed the
expression of these genes in paired CD28null/CD28+ T-cell samples
isolated individually from 10 healthy donors. We confirmed that the
expression levels of NLRP3, PYCARD (ASC), IL-1B, and IL-18 were higher
in all CD28null T-cell samples (Fig. 2B). Nonetheless, the inactive form of
caspase-1 was only more strongly expressed in four of ten (40%)
samples, and the CARD8 gene expression levels were often downreg-
ulated in CD28null T cells. We also observed that in the baseline state,
CD28null T cells showed higher active caspase-1 levels than their CD28+
counterparts (Fig. 2C), and under nigericin stimulation, they were able
to release an active form of the pro-inflammatory IL-1b cytokine
(Fig. 2D). Nigericin alone, but not TNF-a, was sufficient to activate
caspase 1 and induce the release of IL-1b in CD28null T cells, suggesting a
basal preactivating state in these cells.
Changes in the DNA methylation profile in CD28null T cells
contribute to altered TCR signaling and cytotoxicity ability
We examined whether changes in gene expression of CD28null T cells
were due to alterations in the whole-genome methylation profile, using
DNA isolated from the same pools as before. Unsupervised clustering
analysis and scatterplots revealed the reproducibility of the two pools in
both cell types (Fig. S4, Supporting information). We detected 317
probes or DMRs between CD28null and CD28+ T-cell subsets (Table S3,
Supporting information). Of these, 170 probes (160 genes) corre-
sponded to demethylated regions in CD28null T cells, and 147 probes
(136 genes) were de novo-methylated regions (Fig. 3A). Most regions
that lost DNA methylation were located outside CpG islands, while gain
of methylation was associated with CpG islands (Fig. 3B).
To determine the functional relevance of these changes, we
performed GO analysis (Fig. 3C), which revealed an enrichment of
cellular functions related to the functionality of CD4+ T lymphocytes,
such as defense response, immune response, cell adhesion, response to
wounding, cell activation, and inflammatory response. A detailed
analysis of these categories is shown in Fig. S5 and Table S4 (Supporting
information). Differentially methylated genes were associated with
costimulatory molecules (ICOS, PDCD1, CD27, CD226), cytokines
(IL-19, IL-27, IL-24, IL-32, IL-21R, LTA), chemokines (CCL21, CX3CR1,
CXCL1, CCL4, CXCR6), adhesion molecules (ITGAL, KLRG1, LY9),
apoptosis-related molecules (BCL2, FASLG), T-cell activation (WAS,
LCK, SLA-2), and cytotoxicity ability (TYROBP, GZMB, GZMH, LYZ,
CD244, CD59, NKG7, RUNX3; Fig. 3D). KEGG analysis revealed that de
novo-methylated genes in CD28null T cells were mainly associated with
the T-cell receptor (TCR) signaling pathway, whereas demethylated
genes were mainly involved in NK-mediated cell cytotoxicity and
cytokine/chemokine signaling (Table 1).
Senescent CD28null T cells are not able to mount a robust proliferative
response to stimulation (Chou & Effros, 2013). We found many genes
associated with TCR activation and signaling to be de novo-methylated
in CD28null cells (Fig. 3E), for example, the CD3 complex (CD3G and
CD3D), protein tyrosine kinase (PTK) genes (LCK, ITK, TXK), the Grb-2-
related adaptor protein 2 (GRAP2), and the adapter proteins SIT1
(signaling threshold regulating transmembrane adaptor 1) and SLA2
(Scr-like adaptor 2), which negatively regulate TCR signaling. Only the
gene encoding the FYN-binding protein, FYB, was demethylated in
CD28null T cells. Additionally, we examined T-cell diversity and selection
by analyzing TCR (b-chain) usage biases between the CD28+ and
CD28null T-cell subsets (Fig. 4A). The Vb transcription profile revealed
higher Vb/HPRT ratios in CD28null T cells, corresponding to specific
families in each sample (Vb6 and Vb21 in the first individual; Vb8 and
Vb13 in the second), which accumulate a high percentage of alterations,
as shown by the dark red color. The length distribution of CDR3 in
CD28+ T cells shows a Gaussian profile (polyclonal), while CD28null T cells
show a specific CDR3 length distribution, resembling an oligo/mono-
clonal expansion (Fig. 4B).
CpG methylation is inversely correlated with gene expression
in CD28null T cells
Changes in DNA methylation are directly related to modifications in
chromatin structure and gene expression. We analyzed the association
between differentially methylated and expressed genes in CD28+ and
CD28null T cells based on array data. We took data from 170 genes, of
which 31 (18.23%; LILRB3, CX3CR1, GZMB, BCL2, or TYROBP among
others) were demethylated and had a higher level of expression in
CD28null T cells, and 13 (7.64%) genes (such as ITK, LY9, SLA2, or LTA)
were de novo-methylated and downregulated in CD28null T lymphocytes
(Fig. S6, Supporting information). Additionally, we corroborate that
CD28null T cells show a lesser expression of Lck that leads to a diminished
phosphorylation of ZAP70 (Fig. S7, Supporting information). All other
differentially methylated genes without changes in gene expression may
be primed for further alteration upon T-cell activation.
We selected six genes on the basis of their immunological relevance to
validate and replicate the array-based results.Methylationwas analyzedby
bisulfite pyrosequencing, and expression levels were evaluated by flow
cytometry or qRT–PCR in CD28+ and CD28null T-cell subsets isolated from
10 healthy donors (range: 48–92 years; average 70.2  11.6 years).
There was a strong correlation between the methylation level and
expression status (Fig. 5), for example, the chemokine CX3CR1, which is
involved in cellular migration, was demethylated and highly expressed on
the cell surface of CD28null T cells. Similar results were obtained for the
adapter molecule TYROBP (also known as DAP12) and the cytotoxic
molecule GZMB. Both molecules had a higher level of expression in
CD28null T cells due to demethylation, although the degree of demethy-
lation in GZMB was dependent on each donor. Demethylation of the
DAP12 locus could facilitate its expression in CD28null cells, thereby acting
as an activating signal transduction element and enhancing its cytotoxicity
ability. Conversely, the costimulatorymolecule TNFRSF7 (CD27)washighly
methylated in CD28null cells. Although the gene expression array did not
confirm the loss ofCD27 expression in CD28null T cells comparedwith their
CD28+ counterparts, flow cytometry corroborated that all CD28null T cells
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Fig. 2 Overexpression of the inflammasome pathway in CD28null T cells. (A) Difference in the expression of genes related to the inflammasome in CD28null T cells compared
with CD28+ T cells based on whole-genome expression array data. (B) RT–PCR analysis of inflammasome genes (pro-IL-1B, pro-IL-18, CARD8, CASP-1, NLRP3, and PYCARD)
in CD28+ and CD28null T-cell subsets isolated individually from 10 healthy donors. (C) Histograms showing the expression level of the active form of caspase-1 at baseline in
CD28+ and CD28null T cells isolated from three healthy donors. For this purpose, the FLICA probe, which binds only to the active form of caspase, was added to the cell
culture and further detected by flow cytometry. (D) IL-1b levels quantified by ELISA in the cell supernatants of CD28null and CD28+ T cells before and after overnight
stimulation with TNF-a (5 ng mL1), nigericin (10 lM), or both. Histograms are representative of three independent experiments and assayed by duplicates. * P <0.05 versus
CD28+ T cells.
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Fig. 3 Overview of the differentially methylated regions in CD28null T cells and their functional implication. (A) Heat map showing regions differentially methylated (DMRs)
betweenCD28+ andCD28null T cells. A set of 317 probes (296 genes) differed between the T-cell subsets. Datasetswere generated from twobiological replicates per cell type (#1
and #2), obtained from a pool of 12 healthy donors each, to minimize the differences among individuals. Samples were pooled using the same DNA quantity per donor. The
methylation levels vary from unmethylated (b = 0, red) to fully methylated (b = 1, green). (B) Distribution of DMRs in CD28null T cells according to localization in a CpG island or
not. (C)Geneontology (GO) analysis of all DMRs inCD28null T cells (160genes demethylated and136genesdenovo-methylated)with adjusted P < 0.01. The tenmost significant
categories and the number of genes in each are shown. (D) Genes associated with the immune response (cytotoxic molecules, costimulatory molecules, cytokines, and
chemokines) and differentially methylated in CD28null T cells. (E) Illustration of the altered T-cell receptor (TCR) signaling pathway in CD28null T cells. De novo-methylated genes
are highlighted in red; demethylated genes are shown in green.
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lacked this costimulatory molecule. The PTK genes, ITK and TXK, were de
novo-methylated in CD28null T cells, causing their expression to be
downregulated.
Discussion
One of the most consistent age-associated changes in human T cells that
contribute to a decline in immune function is the accumulation of
CD28null T cells. A high frequency of CD28null T cells (up to 50% of total
CD4+ T lymphocytes) has been described in aging and several patholo-
gies associated with chronic inflammatory processes, but also in some
healthy young and middle-aged individuals (Weng et al., 2009). The
generation of this subset has been mostly attributed to pro-inflammatory
environments and repeated antigen stimulation, but the molecular
mechanisms that contribute to its accumulation and maintenance
remain to be elucidated. To date, most studies have been carried out
Table 1 KEGG pathway of differentially methylated genes in CD28null T cells
Pathway P Genes
De novo-methylated genes
hsa04660 T-cell receptor signaling pathway 2.25E-04 ITK, CD3G, CD3D, ICOS, LCK, GRAP2, PDCD1
hsa04060 Cytokine–cytokine receptor interaction 0.0194 CXCL1, CXCR6, FASLG, IL-24, BMPR1B, LTA, EPO
hsa05340 Primary immunodeficiency 0.0333 CD3D, ICOS, LCK
Demethylated genes
hsa04062 Chemokine signaling pathway 0.0016 FGR, CCL21, NCF1, PREX1, CX3CR1, CCL8, WAS, CCL4
hsa04060 Cytokine–cytokine receptor interaction 0.0027 LTBR, CCL21, IL-19, IL-21R, CX3CR1, CCL8, CSF3R, IFNGR2, CCL4
hsa04650 Natural killer cell-mediated cytotoxicity 0.0358 CD244, GZMB, FCGR3B, IFNGR2, TYROBP
Fig. 4 Alterations of the TCRVB repertoire between CD28+ and CD28null T cells. (A) Quantitative and qualitative analysis of TCR repertoire was performed in CD28+ and
CD28null T cells isolated from two healthy donors. Results are displayed as a three-dimensional TcLandscape in which the X, Y, and Z axes represent the 26 human Vb families,
the Vb/HPRT (nonregulated gene) ratios, and the CDR3 lengths, respectively. The percentages of CDR3-LD alterations are represented as a color code from deep blue (30%) to
dark red (+30%). (B) Histograms showing the spectratype analysis of CDR3 lengths for Vb families with the highest Vb/HPRT ratio in the CD28null T-cell subset for each donor.
Fig. 5 Validation of differentially methylated and expressed genes in CD28+ and CD28null T-cell subsets isolated individually from ten healthy donors. For each gene is
shown (from left to right): percentage of methylation based on data from the Illumina Infinium HumanMethylation27 BeadChip array; methylation level determined by
bisulfite pyrosequencing analysis in CD28+ and CD28null T-cell subsets isolated individually from ten healthy donors; mRNA expression levels based on the Illumina expression
array; gene expression analyzed by flow cytometry or qRT–PCR in CD28+; and CD28null T-cell subsets isolated individually from ten healthy donors. Dot plots are
representative of one of the ten experiments. Box plots show the average expression levels of ten donors.* P < 0.05 versus CD28+ T cells.
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with CD28null T cells isolated from patients whose disease etiology,
treatments, and concomitant effects differed substantially, increasing
the variability associated with this cell subset. Our study, carried out with
healthy donors at different ages, demonstrates that DNA methylation
contribute to the functionality and characteristics of CD28null T lympho-
cytes. This is the first report of whole-genome DNA methylation and
expression profiles of CD28null and its CD28+ counterpart. Changes in
DNA methylation levels in the promoter regions of specific genes related
to the immune response, TCR signaling, and cell death pathways reveal
epigenetic control during differentiation to CD28null T cells.
DNA methylation is an essential regulatory mechanism of key
processes of T lymphocytes, such as differentiation to effector cells or
the establishment of a unique phenotype in the memory cells (Li et al.,
2009; Suarez-Alvarez et al., 2012; Komori et al., 2015). Previous studies
have observed global DNA demethylation with aging associated with a
lower level of DNMT1 and DNMT3A/B expression. There is a linear
decrease in DNMT3B expression with age, while the levels of DNMT1
only gradually decreased up to the age of 64 years (Ciccarone et al.,
2016). Moreover, Li et al. (2009) reported that in ‘senescent’ CD28null T
cells, decreased DNMT1 and DNMT3A expression causes demethylation
and overexpression of CD70, PRF, and KIR2DL4 genes. Here, we show
that changes in the global DNA methylation profile in CD28null T cells are
equally associated with gain and loss of methylation in specific genes.
We observed that demethylated regions are mainly associated with
genes related to immune function, such as cytotoxicity response,
cytokine/chemokine signaling, or costimulation. Results confirmed by
bisulfite sequencing, the gold standard for methylation studies, show
that CD28+ T cells isolated from healthy donors of various ages have
methylation levels > 80% for CX3CR1, while their CD28null counterparts
show levels of 20–40%. When we examined the expression of this
chemokine by expression arrays and flow cytometry, all CD28null T cells
showed a higher level of expression of CX3CR1, but the CD28+ subsets
lacked this receptor. CX3CR1, which is expressed mainly in NK, CD8+ T,
dendritic, endothelial and epithelial cells, and monocytes, but not in
CD4+ T lymphocytes, is involved in T-cell migration to inflamed tissue in
response to a gradient of their ligand, fractalkine (CX3CL1; Fong et al.,
1998). Thus, DNA demethylation in the CX3CR1 gene promoter confers
on the CD28null T cells the ability to migrate toward inflammatory
tissues, where they exert their inflammatory and cytotoxic effects.
Overexpression of CX3CR1 in IL-7Ralow effector-memory CD8+ T cells is
also known to be due to loss of methylation (Shin et al., 2015). We
observed that expression of most genes associated with the cytotoxic
ability acquired by CD28null T cells is also regulated by DNA methylation.
These include the following: TYRO protein tyrosine kinase binding
protein (TYROBP), which acts as an activating signal transduction
element associated with KIR family proteins (Mulrooney et al., 2013);
CD59 cell surface glycoprotein, which functions as a coreceptor and
activates human NK-cell-mediated cytotoxicity (Marcenaro et al., 2003);
NKG7 (GMP-17) granule membrane protein (Medley et al., 1996);
RUNX3 transcription factor, which regulates the expression of genes
involved in the differentiation of CTLs such as EOMES, IFNG, PRF1 (Cruz-
Guilloty et al., 2009), and the cytotoxic molecules, granzyme B and H.
Our results demonstrate the essential role of DNA demethylation in
conferring cytotoxic properties on differentiated CD28null T cells.
The costimulatory molecule CD28 plays multiple roles in T-cell
activation, proliferation, and survival. These CD4+ T lymphocytes that
lose CD28 expression display striking features, such as reduced T-cell
receptor (TCR) diversity, and defects in the antigen-induced proliferation
compromising the immune response (Maly & Schirmer, 2015). Quanti-
tative analysis of the TCR repertoire demonstrates that CD28null T cells
are highly enriched in specific Vb families and show an oligo/monoclonal
expansion of the CDR3 segments, leading to a constrained immune
response that varies between individuals. This suggests that CD28null T
cells might be generated in response to repeated antigen exposure,
although antigens differ between individuals and pathologies. We also
found that genes associated with TCR signaling are de novo-methylated
in CD28null T cells. Following TCR engagement, Lck is brought into
proximity of the CD3 complex and phosphorylates ITAM motifs to
further recruit the Zap70 protein (Huse, 2009). After that, Zap70 can be
phosphorylated by Lck and together with the Itk and Txk kinases
phosphorylate proteins of the LAT/Slp76 complex. These sequential steps
are essential to lead to T-cell activation and proliferation. In CD28null T
cells, we show that hypermethylation of LCK gene is associated with less
phosphorylation of the Zap70 that could damage TCR-mediated initial
activation (Limbach et al., 2016). Moreover, de novo methylation of ITK
and TXK genes reduces the expression of these kinases. A decline in
levels of tyrosine-phosphorylated proteins with age had been associated
with defects in TCR activation pathways (Pawelec et al., 2001). The
decrease in Lck in CD28null T cells may result in partial TCR activation and
trigger proliferative hyporesponsiveness. The greater overexpression of
the KLRG1 co-inhibitory receptor in CD28null T cells by loss of
methylation could interfere with T-cell proliferation via Akt-mediated
changes in cyclins and cyclin inhibitors (Henson et al., 2009). Thus,
epigenetic silencing of key genes of the TCR pathway may contribute to
the slower division of CD28null T cells in response to antigen activation.
By contrast, we observed that genes involved in the inflammasome
configuration (NLRP3, CASP-1, PYCARD, IL-1B, and IL-18) and caspase-1
activation (HMGB1 and CTSB) are stronger upregulated in CD28null T
cells vs. their CD28+ counterparts. These expression changes lead to a
higher susceptibility of these cells to the activation of the inflammasome
and IL-1b release. Thus, CD28null T cells could show a baseline
preactivation state that under certain environmental stimuli contributes
to trigger a chronic inflammatory process as had been reported in CD4+
T cells from HIV-1 patients (Doitsh et al., 2014).
The longevity and persistence over time of CD28null T cells has been
associated with a high apoptosis resistance (Vallejo et al., 2000).
Previous studies and data from our expression arrays indicate that genes
involved in the extrinsic and intrinsic apoptosis pathways are differen-
tially expressed in CD28+ and CD28null T cells. In CD28null T cells, the FasL
death receptor-dependent pathway is mainly impaired by increased
expression of the antiapoptotic molecule FLIP (also known as CASPER or
CFLAR), which interacts with caspase-8 due to its structural similarity
(Majkut et al., 2014). Alterations in the mitochondrial-dependent
pathway are attributed to the lower expression levels of the Bim and
Bax pro-apoptotic molecules in these cells. Unlike what was noted by
Kovalcsik et al. (2015), we observed significant overexpression of the
antiapoptotic molecules Bcl-2, Bcl-x (BCL2L1 gene), and Mcl-1 (BCL2L3
gene). The BCL2 gene is significantly demethylated in CD28null T cells.
Other apoptosis inhibitors, such as BIRC2 (encoding cIAP1 protein) and
BIRC3 (encoding cIAP2 protein), are upregulated while the caspase
activator DIABLO is downregulated in CD28null T cells. Thus, changes in
the transcriptional regulation of apoptotic molecules and their regulators
might be responsible for the resistance of CD28null T cells to apoptosis.
Modulating the fine balance between apoptotic signals might be a useful
objective to avoid the accumulation of these cells over time. In fact,
proteasome inhibitors are known to restore the sensitivity of CD28null T
cells to apoptosis, thereby favoring their elimination (Kovalcsik et al.,
2015). Our results suggest that other forms of cell death, such as
pyroptosis or necroptosis, could also be misrepresented in these cells,
although this requires further detailed investigation.
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In summary, we demonstrate that loss of the CD28 molecule in CD4+
T lymphocytes during aging is associated with profound DNA methyla-
tion changes that contribute to the acquisition of the unique biological
and functional properties observed in this cell subset. Differentially
methylated regions are strongly associated with gene expression
changes, leading to changes in the cytotoxic response, TCR signaling,
and cell death pathways. Identifying the mechanisms regulating these
pathways will provide a better understanding of how these pathogenic
and ‘senescent’ CD28null T cells are generated and suggest new
strategies for blocking the function and longevity of these cells in the
course of T-cell aging.
Experimental procedures
Samples, cell separation, and reagents
Blood from healthy donors at different ages was obtained from the
Asturias Transfusion Centre and the Internal Medicine Department of
the Hospital Central de Asturias, Spain, after obtaining informed consent
in accordance with the Declaration of Helsinki and following approval by
the hospital’s Ethics Committee. Healthy status was defined as the
absence of autoimmune diseases, cancer, infectious diseases, dementia,
and cardiovascular diseases that could interfere with the study.
Peripheral blood mononuclear cells (PBMCs) were isolated by density
gradient centrifugation. CD28null and CD28+ T cells were purified using a
CD4 Multisort kit and CD28 MicroBead kit (Miltenyi Biotec, Bergisch
Gladbach, Germany) or sorted with a BD FACSARIA II cytometer (BD
Bioscience, San Jose, CA, USA) after staining with CD4-APC and CD28-
FITC monoclonal antibodies (Abs; BioLegend, San Diego, CA, USA).
Purity was > 95% for all samples. Staurosporine (50 nM; Enzo Life
Science, Lausen, Switzerland) was added to isolated PBMCs for 18 h to
induce apoptosis.
DNA and RNA extraction
Genomic DNA and total RNAwere isolated from samples using theQiAmp
DNA Micro kit (Qiagen, Hilden, Germany) and RNAqueous Micro kit
(Thermo Fisher Scientific, Waltham, MA, USA), respectively, following the
manufacturers’ instructions. Quality and quantity were assessed using an
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA)
and a fluorometric Qubit 2.0 assay (Invitrogen, Carlsbad,CA,USA),
respectively.
Whole-genome DNA methylation arrays
Samples were pooled using the same DNA quantity for each donor.
DNA methylation was analyzed using an Illumina Infinium
HumanMethylation27 BeadChip array (Illumina Inc. San Diego, CA,
USA). Genomic DNA (500 ng) was bisulfite-converted with the EZ DNA
methylation kit (Zymo Research Corp. Irvine, CA, USA) following the
manufacturer’s protocol, then whole-genome amplified, enzymatically
fragmented, and purified to hybridize to the locus-specific oligonu-
cleotides on the BeadArray. Fluorescent signals were measured with the
BeadStation GX scanner (Illumina Inc.), and raw data were decoded with
GenomeStudio software (Illumina Inc.). The amount of methylated DNA
for a specific cytosine is represented by the average beta value, which
ranges between 0 (completely unmethylated) and 1 (completely
methylated). Datasets were generated from two biological replicates
per cell type (CD28null and CD28+), each obtained from a pool of 12
healthy donors.
Whole-genome gene expression arrays
Samples were pooled using the same RNA quantity for each donor,
and their gene expression levels were characterized using Human
HT12 v3 BeadChips (Illumina Inc.). cRNA was synthesized with a
TargetAmpTM Nano-gTM Biotin-aRNA Labeling Kit for the Illumina R
System (Epicentre, Illumina Inc. Madison, WI, USA), and subsequent
amplification, labeling, and hybridization were performed following
Illumina’s protocol. Raw data were decoded with GenomeStudio
software (Illumina Inc.) to obtain a final report (sample probe profile).
Datasets were generated using the same pools of healthy donors as
for the methylation arrays.
Statistical and functional analysis
Raw methylation and expression data were background-corrected, log2-
transformed, and quantile-normalized using the R packages from the
Bioconductor project and lumi package (Gentleman et al., 2004; Du
et al., 2008). Probabilities were corrected for multiple testing by
determining the false discovery rates (FDRs) with the Benjamin–
Hochberg procedure. Probes with detection P-values > 0.01 and sex
chromosomes were excluded from the analysis. For methylation arrays,
we used b values as a quantitative measure of DNA methylation levels of
specific CpGs. To analyze the differentially methylated regions (DMRs),
we considered probes with values of FDR-adjusted P < 0.01 and b ≥ 0.7
(70%, hypermethylated probes) or ≤ 0.3 (30%, unmethylated probes).
To compare subsets, we only considered probes in CD28null T cells
showing a difference of ≥ 20% (Db ≥ 0.2) relative to their CD28+
counterpart. For expression data, a gene was considered differentially
expressed if it had a value of FDR-adjusted P < 0.05 and a > 1.5-fold
change (FC) in expression. Gene ontology (GO) enrichment was
performed with the web-based DAVID GO tool (Huang da et al.,
2009). Raw array data have been submitted to the NCBI Gene Expression
Omnibus (GEO) under accession number GSE78942 (https://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE78942).
Bisulfite pyrosequencing
Genomic DNA (500 ng) was bisulfite-converted with an EZ DNA
methylation kit (Zymo Research Corp.) following the manufacturer’s
protocol. Primers were designed with PYROMARK ASSAY DESIGN 2.0
software (available upon request). Pyrosequencing was performed with
the PYROMARK kit and the Pyrosequencing Vacuum Prep Tool (Qiagen).
Methylation was quantified using the PYROMARK Q24 system (Biotage,
Uppsala, Sweden).
Quantitative real-time PCR
Total RNA was transcribed with the High Capacity cDNA Reverse
Transcription kit (Applied Biosystem). Gene expression was quantified by
real-time PCR on a Step One Plus RT–PCR System (Applied Biosystems)
using TaqMan assays (Applied Biosystems, Foster City, CA, USA) or
designed primers (Table S5, Supporting information). The numbers of
transcripts were calculated using threshold cycle (Ct) values standardized
to GAPDH, using the 2-(DCt) method.
TCR landscape
The global TCR repertoire was analyzed by TcLandscape, which
combines the analysis of Vb chain gene segment usage, CDR3 length
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distribution (CDR3-LD) level and a quantitative PCR assessment of all
CDR3 length-restricted mRNAs in each family. For this purpose, mRNA
from CD28+ and CD28null T cells was isolated from two healthy donors.
The analysis was carried out by TcLand Expression Inc., Huningue, France
(www.tcland-expression.com). The results were displayed as a three-
dimensional TcLandscape.
Flow cytometry
The following Abs were used: CD4-APC, CD3-PERCP, CD28-FITC,
CX3CR1-PE, CD27-PE, Granzyme-B-PE, and isotype-matched controls
(BioLegend). For intracellular staining, cells were fixed, permeabilized
with a Fixation/Permeabilization kit (Immunostep, Salamanca, Spain),
and stained with anti-Lck and antiphospho-Zap-70 Abs (Cell Signaling
Technology, Danvers, MA, USA) and a secondary antibody conjugated
to phycoerythrin (Biolegend). The active form of caspase-1 was
determined with the FAM-FLICA in vitro caspase-1 detection kit
(ImmunoChemistry Technologies, Bloomington, MN, USA). Apoptosis
was quantified by staining with CD28-PE and CD4-APC and FITC
Annexin V/7AAD Apoptosis detection kit, following the manufacturer’s
instructions. Cells were analyzed on a Gallios Flow Cytometer (Beckman
Coulter, Inc. Fullerton, CA, USA)
Inflammasome activation and IL-1b ELISA
To activate NLRP3 inflammasome, cells (2 9 105) were primed with TNF-
a (5 ng mL1; PeproTech EC Ltd. London, UK) for 1 h at 37 °C, followed
by treatment with nigericin (10 lM; InvivoGen, San Diego, CA, USA)
overnight. Free-cell culture supernatants were collected, and human IL-
1b (Biolegend) levels were quantified by ELISA, following the manufac-
turer’s instructions.
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